Morgan Stanley cuts PICC Group target price to Rmb8.70, maintains Equal-weight
AI summary card
Morgan Stanley cuts PICC Group target price to Rmb8.70, maintains Equal-weight
The report updates the model after FY25 results, lowers life insurance and group earnings forecasts, and sees P&C as resilient with improving life and health insurance, but limited valuation appeal at current A-share levels.
- 2026E and 2027E life insurance NPAT forecasts were cut by 13.5% and 15.8%, respectively, while group NPAT/EPS forecasts were cut by 6.4% and 6.7%, respectively.
- The SOTP target price was cut 8% to Rmb8.70, with P&C valuation adjusted to 1.05x 2026E PB.
- P&C still has about one-third market share and underwriting advantages, and the easing regulatory backdrop for non-auto insurance is supportive.
- Life insurance quality is improving but still lags peers, while health insurance has had strong growth momentum over the past three years and could see further re-rating.
- The bull case is Rmb11.80 and the bear case is Rmb4.10, mainly depending on investment trends, VNB growth, CoR, and the interest-rate environment.
Report interpretation
Overview
Morgan Stanley released this risk-reward update on PICC Group 601319.SS, re-rating the model after FY25 results. The report lowered 2026E and 2027E earnings forecasts for the life insurance business, while leaving P&C and health insurance forecasts broadly unchanged and adding 2028 forecasts. The target price was cut 8% from the prior level to Rmb8.70, and the Equal-weight rating was maintained.
Core views
The core view is that PICC P&C has market share, underwriting strength, and support from a more favorable non-auto insurance regulatory backdrop; after the new management team settles in during 2026, steady growth may still be sustained. Life insurance quality is catching up with peers but still lags, while health insurance has shown strong growth over the past three years and may deserve further re-rating. The constraint is that, relative to other A-share insurers, PICC's current valuation is not attractive enough, so the neutral rating is maintained.
Analysis framework
The report uses a SOTP segment valuation framework, valuing P&C, life insurance, health insurance, and the group separately, and setting bull, base, and bear scenarios. In the base case, PICC Life is valued at 1.0x EV with a 17% EV discount, PICC Health at 2.3x EV, assuming ROEV of about 15% and about 28%, a cost of capital of 13%, perpetual growth of 1%, and a 15% discount applied to the group's SOTP valuation.
Methodology notes
sum-of-the-parts valuation
Values P&C, life insurance, health insurance, and the group separately and then sums them, with a group discount applied to reflect differences in business quality, growth, and capital returns.
embedded value multiple
Life insurance and health insurance are valued using EV multiples; in the base case, the report applies 1.0x EV to PICC Life and 2.3x EV to PICC Health.
price-to-book/book value valuation
P&C and the group are valued using PB or BV-related multiples, and in the base case P&C is adjusted to 1.05x 2026E PB.
bull-base-bear risk-reward analysis
The report uses bull, base, and bear scenarios to describe target price upside and downside, with key variables including investment returns, CoR, VNB growth, interest rates, the A-share market, and life insurance sales quality.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- PICC Group 601319.SSresearch coverage
- Strengths
- P&C business maintains market leadership, with about one-third market share and strong underwriting results; life insurance and health insurance quality transformation is progressing, and health insurance growth momentum is strong.
- Weaknesses
- Life insurance results were weaker than expected in FY25, and 2026E and 2027E earnings forecasts were lowered; A-share valuation appeal is limited relative to insurance peers.
- Comparison
- The report notes that life insurance is catching up with peers but still has a gap, and its valuation appeal is weaker than that of some insurance peers.
- Risks
- Lower investment returns, worsening CoR, slower life insurance sales, weaker-than-expected VNB margin improvement, intensifying competition, and higher catastrophe claims.
- PICC P&Ccore business segment
- Strengths
- Leading market share, resilient underwriting results, and a more favorable regulatory backdrop for non-auto insurance.
- Weaknesses
- Group valuation may come under pressure if auto and non-auto insurance profitability declines.
- Comparison
- P&C is the group's stronger business line.
- Risks
- Renewed competition, rising catastrophe claims, and worsening CoR.
- PICC Lifelife insurance subsidiary
- Strengths
- Business quality is improving, and VNB growth plus margin improvement are upside drivers.
- Weaknesses
- FY25 performance was weaker than expected, and there is still a gap versus peers.
- Comparison
- It is catching up with peers but has not fully closed the gap.
- Risks
- Slower sales, weaker-than-expected VNB margin improvement, and low interest rates weighing on investment returns.
- PICC Healthhealth insurance segment
- Strengths
- Strong growth momentum over the past three years, with potential for further re-rating.
- Weaknesses
- Valuation depends on sustained earnings contribution and ROEV performance.
- Comparison
- Compared with life insurance, health insurance has more pronounced growth momentum.
- Risks
- Earnings contribution falling short of expectations or a slowdown in growth momentum.
Key data
- RatingEqual-weightThe report sees valuation as fair and maintains a neutral view.
- Target priceRmb8.70SOTP target price cut by 8%.
- Bull-case valueRmb11.80Assumes improved investment trends, strong P&C CoR performance, and VNB growth remaining above 15%.
- Bear-case valueRmb4.10Assumes worsening CoR and investment performance, weak sales, and a prolonged low-rate environment.
- Life insurance NPAT forecast revision2026E -13.5%; 2027E -15.8%Driven by weaker-than-expected life insurance performance in 2025.
- Group NPAT/EPS forecast revision2026E -6.4%; 2027E -6.7%P&C and health insurance forecasts are broadly unchanged.
- Base-case valuation assumptionsPICC Life 1.0x EV; PICC Health 2.3x EV; cost of capital 13%; perpetual growth 1%PICC Life valuation includes a 17% EV discount, and the group SOTP discount is 15%.
Impact & implications
For investors, the implication is that PICC Group is not a clearly undervalued offensive name in the near term, and is better viewed as an insurance stock with solid fundamentals and relatively balanced valuation return. If investment income, the A-share market, interest rates, and life insurance VNB quality improve, valuation could re-rate upward; if P&C claims or competitive pressure rise, or if life insurance sales and margin recovery fall short of expectations, target price and rating will face downside pressure.
Risks
- P&C CoR deterioration or auto and non-auto insurance profitability coming in below expectations.
- Renewed competition and higher claims from catastrophe losses.
- Life insurance sales and margin improvement slower than expected, with VNB growth missing targets.
- Investment returns falling to 3.5% or below, with the low-rate environment persisting.
- The A-share market and interest rates performing weaker than expected.
- DPS growth disappointing and insufficient improvement in shareholder returns.
What to watch
- 2026 P&C growth, underwriting results, and CoR performance.
- Life insurance VNB growth, VNB margin, and the pace of business quality improvement.
- Sustained contributions from health insurance and life insurance to group earnings.
- A-share market performance, interest-rate changes, and investment yield trends.
- Shareholder returns and DPS growth.
- Execution effectiveness after management changes.